과제정보
This study was supported by a National Research Foundation (NRF) grant (2017R1A2A2A01005212, NRF-2017M3A9B4028208, NRF-2017M3A9B4061408) and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI13C2098).
참고문헌
- Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet 2015;386:1683-1697 https://doi.org/10.1016/S0140-6736(15)00462-6
- Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996;737:195-200 https://doi.org/10.1016/0006-8993(96)00729-9
- Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P. Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation? J Chem Neuroanat 2000;20:253-257 https://doi.org/10.1016/S0891-0618(00)00096-X
- Cepeda IL, Flores J, Cornfeldt ML, O'Kusky JR, Doudet DJ. Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of Parkinson disease. J Neuropathol Exp Neurol 2007;66:576-584 https://doi.org/10.1097/nen.0b013e318093e521
- Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord 2005;11 Suppl 1:S3-7 https://doi.org/10.1016/j.parkreldis.2004.10.012
- Chen Z. Cell Therapy for Parkinson's disease: new hope from reprogramming technologies. Aging Dis 2015;6:499-503 https://doi.org/10.14336/AD.2014.1201
- Fu MH, Li CL, Lin HL, Chen PC, Calkins MJ, Chang YF, Cheng PH, Yang SH. Stem cell transplantation therapy in Parkinson's disease. Springerplus 2015;4:597 https://doi.org/10.1186/s40064-015-1400-1
- Lindvall O. Treatment of Parkinson's disease using cell transplantation. Philos Trans R Soc Lond B Biol Sci 2015;370:20140370 https://doi.org/10.1098/rstb.2014.0370
- Przedborski S. Inflammation and Parkinson's disease pathogenesis. Mov Disord 2010;25 Suppl 1:S55-57 https://doi.org/10.1002/mds.22638
- Damien P, Allan DS. Regenerative therapy and immune modulation using umbilical cord blood-derived cells. Biol Blood Marrow Transplant 2015;21:1545-1554 https://doi.org/10.1016/j.bbmt.2015.05.022
- Bayarsaikhan E, Bayarsaikhan D, Lee J, Son M, Oh S, Moon J, Park HJ2, Roshini A2, Kim SU4, Song BJ5, Jo SM6, Byun K3, Lee B3. Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics. Int J Nanomedicine 2016;10 Spec Iss:281-292 https://doi.org/10.2147/IJN.S95077
- Kalea AZ, Schmidt AM, Hudson BI. Alternative splicing of RAGE: roles in biology and disease. Front Biosci (Landmark Ed) 2011;16:2756-2770 https://doi.org/10.2741/3884
- Son M, Kang WC, Oh S, Bayarsaikhan D, Ahn H, Lee J, Park H, Lee S, Choi J, Lee HS, Yang PC, Byun K, Lee B. Advanced glycation end-product (AGE)-albumin from activated macrophage is critical in human mesenchymal stem cells survival and post-ischemic reperfusion injury. Sci Rep 2017;7:11593 https://doi.org/10.1038/s41598-017-11773-1
- Son M, Oh S, Park H, Ahn H, Choi J, Kim H, Lee HS, Lee S, Park HJ, Kim SU, Lee B, Byun K. Protection against RAGE-mediated neuronal cell death by sRAGE-secreting human mesenchymal stem cells in 5xFAD transgenic mouse model. Brain Behav Immun 2017;66:347-358 https://doi.org/10.1016/j.bbi.2017.07.158
- Byun K, Yoo Y, Son M, Lee J, Jeong GB, Park YM, Salekdeh GH, Lee B. Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases. Pharmacol Ther 2017;177:44-55 https://doi.org/10.1016/j.pharmthera.2017.02.030
- Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-955 https://doi.org/10.1172/JCI200114002
- Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, Schmidt AM. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117-1128 https://doi.org/10.1007/s00018-002-8491-x
- Byun K, Bayarsaikhan E, Kim D, Kim CY, Mook-Jung I, Paek SH, Kim SU, Yamamoto T, Won MH, Song BJ, Park YM, Lee B. Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer's disease. PLoS One 2012;7:e37917 https://doi.org/10.1371/journal.pone.0037917
- Byun K, Bayarsaikhan E, Kim D, Son M, Hong J, Jeong GB, Paek SH, Won MH, Lee B. Activated microglial cells synthesize and secrete AGE-albumin. Anat Cell Biol 2012;45:47-52 https://doi.org/10.5115/acb.2012.45.1.47
- Wang H, La Russa M, Qi LS. CRISPR/Cas9 in genome editing and beyond. Annu Rev Biochem 2016;85:227-264 https://doi.org/10.1146/annurev-biochem-060815-014607
- Chang CY, Ting HC, Su HL, Jeng JR. Combining induced pluripotent stem cells and genome editing technologies for clinical applications. Cell Transplant 2018;27:379-392 https://doi.org/10.1177/0963689718754560
- Komor AC, Badran AH, Liu DR. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 2017;168:20-36 https://doi.org/10.1016/j.cell.2016.10.044
- Hendriks WT, Warren CR, Cowan CA. Genome editing in human pluripotent stem cells: approaches, pitfalls, and solutions. Cell Stem Cell 2016;18:53-65 https://doi.org/10.1016/j.stem.2015.12.002
- Ceasar SA, Rajan V, Prykhozhij SV, Berman JN, Ignacimuthu S. Insert, remove or replace: a highly advanced genome editing system using CRISPR/Cas9. Biochim Biophys Acta 2016;1863:2333-2344 https://doi.org/10.1016/j.bbamcr.2016.06.009
- Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013;31:397-405 https://doi.org/10.1016/j.tibtech.2013.04.004
- Tycko J, Myer VE, Hsu PD. Methods for optimizing CRISPR-Cas9 genome editing specificity. Mol Cell 2016;63:355-370 https://doi.org/10.1016/j.molcel.2016.07.004
- Chandrasegaran S. Recent advances in the use of ZFN-mediated gene editing for human gene therapy. Cell Gene Ther Insights 2017;3:33-41 https://doi.org/10.18609/cgti.2017.005
- Renaud JB, Boix C, Charpentier M, De Cian A, Cochennec J, Duvernois-Berthet E, Perrouault L, Tesson L, Edouard J, Thinard R, Cherifi Y, Menoret S, Fontaniere S, de Croze N, Fraichard A, Sohm F, Anegon I, Concordet JP, Giovannangeli C. Improved genome editing efficiency and flexibility using modified oligonucleotides with TALEN and CRISPR-Cas9 nucleases. Cell Rep 2016;14:2263-2272 https://doi.org/10.1016/j.celrep.2016.02.018
- Luo Y, Rao M, Zou J. Generation of GFP reporter human induced pluripotent stem cells using AAVS1 safe harbor transcription activator-like effector nuclease. Curr Protoc Stem Cell Biol 2014;29:5A.7.1-18
- Munch G, Westcott B, Menini T, Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids 2012;42:1221-1236 https://doi.org/10.1007/s00726-010-0777-y
- Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010;6:193-201 https://doi.org/10.1038/nrneurol.2010.17
- Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs 2001;10:1977-1987 https://doi.org/10.1517/13543784.10.11.1977
- Walker DG, Lue LF. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J Neurosci Res 2005;81:412-425 https://doi.org/10.1002/jnr.20484
피인용 문헌
- The Receptor for Advanced Glycation End Products (RAGE) and DIAPH1: Implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system vol.126, 2019, https://doi.org/10.1016/j.neuint.2019.03.012
- CRISPR/Cas9 facilitates genomic editing for large-scale functional studies in pluripotent stem cell cultures vol.138, pp.11, 2019, https://doi.org/10.1007/s00439-019-02071-z
- Recent advances in genome editing of stem cells for drug discovery and therapeutic application vol.209, 2019, https://doi.org/10.1016/j.pharmthera.2020.107501
- Mesenchymal Stem Cell Derived Extracellular Vesicles for Repairing the Neurovascular Unit after Ischemic Stroke vol.10, pp.4, 2019, https://doi.org/10.3390/cells10040767
- Strategies to Potentiate Paracrine Therapeutic Efficacy of Mesenchymal Stem Cells in Inflammatory Diseases vol.22, pp.7, 2019, https://doi.org/10.3390/ijms22073397
- Combinational Therapy of Cardiac Atrial Appendage Stem Cells and Pyridoxamine: The Road to Cardiac Repair? vol.22, pp.17, 2019, https://doi.org/10.3390/ijms22179266
- Mesenchymal Stem/Stromal Cell Therapy in Blood-Brain Barrier Preservation Following Ischemia: Molecular Mechanisms and Prospects vol.22, pp.18, 2021, https://doi.org/10.3390/ijms221810045